## ZBH: Zimmer Biomet Holdings, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.94 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($86.87)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 0, Bearish: 1)

**1. Zimmer Biomet (ZBH): Reassessing Valuation After Mixed Q3 Results and Growing Investor Concerns**
- Source: Sahm | 20251211T190856 | Neutral | Relevance: 100%
- Zimmer Biomet's Q3 results showed mixed performance, with organic sales up but overall revenue missing expectations, leading to stock underperformance. Despite trading below analyst targets and intrinsic value estimates, the company's valuation narrative suggests it is 10.3% undervalued due to growing profitability and an expanding product mix. However, near-term execution challenges and competition could impact this outlook.

**2. Zimmer Biomet Stock: Is ZBH Underperforming the Health Care Sector?**
- Source: Markets Financial Content | 20251210T045500 | Somewhat-Bearish | Relevance: 100%
- Zimmer Biomet Holdings, Inc. (ZBH) is a large-cap medical technology company specializing in orthopedic implants. The company's stock has underperformed the Health Care Select Sector SPDR Fund (XLV) over various periods, including a 12.7% decline year-to-date compared to XLV's 9% gain. ZBH also lags behind competitor Penumbra, Inc. (PEN) and analysts currently rate ZBH as a "Hold" with an 11.3% upside to the mean price target.

**3. 31,313 Shares in Zimmer Biomet Holdings, Inc. $ZBH Acquired by Occudo Quantitative Strategies LP**
- Source: MarketBeat | 20251212T125813 | Somewhat-Bullish | Relevance: 100%
- Occudo Quantitative Strategies LP has acquired a new stake of 31,313 shares in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the second quarter, valued at approximately $2.856 million, contributing to institutional investors owning 88.89% of the company. Zimmer Biomet recently reported Q3 EPS of $1.90, slightly above expectations, with revenue of $2.0 billion and FY2025 guidance at EPS 8.10â€“8.30. The stock maintains a "Hold" consensus rating from analysts, with a target price of $108.25.

**4. California Public Employees Retirement System Has $60.75 Million Stock Holdings in Zimmer Biomet Holdings, Inc. $ZBH**
- Source: MarketBeat | 20251210T095913 | Neutral | Relevance: 100%
- The California Public Employees Retirement System significantly increased its stake in Zimmer Biomet Holdings, Inc., boosting its holdings by 107.9% to 666,049 shares, valued at $60.75 million. Other institutional investors, including Ameriprise Financial Inc. and Dodge & Cox, also made substantial changes to their positions in the medical equipment provider. Zimmer Biomet recently reported robust quarterly earnings, surpassing analyst estimates, and has provided positive guidance for FY 2025.

**5. Zimmer Biomet Stock: Is ZBH Underperforming the Health Care Sector?**
- Source: Barchart.com | 20251210T095813 | Bearish | Relevance: 100%
- Zimmer Biomet Holdings, Inc. (ZBH) is underperforming the Health Care Select Sector SPDR Fund (XLV) and rival Penumbra, Inc. (PEN), with its stock declining significantly from its 52-week high. Despite a positive Q3 adjusted EPS, the company's net sales fell short of consensus, contributing to its "Hold" rating from analysts. The stock has shown intense volatility, dipping below key moving averages.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-11 | Citigroup | $94 | $98 | -4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-11 | Citigroup | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 9 ($0.00M) |
| Sells | 1 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 57.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.8% (+0.2%)
- Dodge & Cox Inc.: 11.7% (+5.1%)
- Blackrock Inc.: 8.1% (+0.2%)
- Price (T.Rowe) Assoc: 7.6% (+1.9%)
- State Street Corpora: 4.4% (-1.3%)

### Key Risks

1. Long-term trend broken: trading 7.1% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.94 indicates undervaluation relative to growth. Forward P/E 10.8x stretched relative to 4% growth. Balance sheet: strong liquidity (2.4x). Analyst sentiment negative (1 target cuts vs 0 raises). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $18.2B |
| Beta | 0.61 |
| 52W Range | $85.33 - $114.44 |
| Short Interest | 4.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.94 |
| Forward P/E | 10.8 |
| Current P/E | 11.2 |
| YoY Growth | 4.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 stable at -1.6% (minimal 5-day change). Below STRENGTH zone by 5.7pp (needs >4.0% for momentum thesis). MRS_5 turning positive (0.5%) - potential reversal signal. Below SMA200 (0.93x), long-term trend not supportive. RSI neutral at 43. OFD pattern: -SLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.65% (CS: 24) | Neutral |
| RSI_14 | 42.9 | Neutral |
| MACD Histogram | 0.03 | Bullish |
| vs SMA20 | 0.987x | Below |
| vs SMA50 | 0.957x | Below |
| vs SMA200 | 0.929x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $91.59
- **Stop Loss:** $86.87 (5.2% risk)
- **Target:** $101.03 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 211
- **Position Value:** $19,325.49
- **Portfolio %:** 19.33%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-02-05 (Est: $2.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.87 | $1.90 | +1.8% |
| 2025Q2 | $1.98 | $2.07 | +4.8% |
| 2025Q1 | $1.77 | $1.81 | +2.3% |
| 2024Q4 | $2.29 | $2.31 | +0.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*